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Abstract
Objectives To measure the effect of the adverse events within 35 days
of transrectal ultrasound guided biopsy from the perspective of
asymptomatic men having prostate specific antigen (PSA) testing; to
assess early attitude to re-biopsy; to estimate healthcare resource use
associated with adverse events due to biopsy; and to develop a
classification scheme for reporting adverse events after prostate biopsy.
DesignProspective cohort study (Prostate Biopsy Effects: ProBE) nested
within Prostate Testing for Cancer and Treatment (ProtecT) study.
Participants Between 1999 and 2008, 227 000 community dwelling
men aged 5069 years were identified at 352 practices and invited to
counselling about PSA testing. 111 148 attended a nurse led clinic in
the community, and 10 297 with PSA concentrations of 3-20 ng/mL were
offered biopsy within ProtecT. Between February 2006 and May 2008,
1147/1753 (65%) eligible men (mean age 62.1 years, mean PSA 5.4
ng/mL) having 10 core transrectal ultrasound guided biopsy under
antibiotic cover in the context of ProtecT were recruited to the ProBE
study.
Outcome measures Purpose designed questionnaire administered at
biopsy and 7 and 35 days after the procedure to measure frequency
and effect of symptoms related to pain, infection, and bleeding; patients’
attitude to repeat biopsy assessed immediately after biopsy and 7 days
later; participants’ healthcare resource use within 35 days of biopsy
evaluated by questionnaire, telephone follow-up, and medical note
review; each man’s adverse event profile graded according to symptoms
and healthcare use.
Results Pain was reported by 429/984 (43.6%), fever by 172/985
(17.5%), haematuria by 642/976 (65.8%), haematochezia by 356/967
(36.8%), and haemoejaculate by 605/653 (92.6%) men during the 35
days after biopsy. Fewermen rated these symptoms as amajor/moderate
problem—71/977 (7.3%) for pain, 54/981 (5.5%) for fever, 59/958 (6.2%)
for haematuria, 24/951 (2.5%) for haematochezia, and 172/646 (26.6%)
for haemoejaculate. Immediately after biopsy, 124/1142 (10.9%, 95%
confidence interval 9.2 to 12.8) men reported that they would consider
further biopsy a major or moderate problem: seven days after biopsy,
this proportion had increased to 213/1085 (19.6%, 17.4% to 22.1%). A
negative attitude to repeat biopsy was associated with unfavourable
experience after the first biopsy, particularly pain at biopsy (odds ratio
8.2, P<0.001) and symptoms related to infection (7.9, P<0.001) and
bleeding (4.2, P<0.001); differences were evident between centres
(P<0.001). 119/1147 (10.4%, 8.7% to 12.3%) men reported consultation
with a healthcare professional (usually their general practitioner), most
commonly for infective symptoms. Complete data for all index symptoms
at all time points were available in 851 participants. Symptoms and
healthcare use could be used to grade these men as follows: grade 0
(no symptoms/contact) 18 (2.1%, 1.3% to 3.3%); grade 1 (minor
problem/no contact) 550 (64.6%, 61.4% to 67.8%); grade 2
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(moderate/major problem or contact) 271 (31.8%, 28.8% to 35.1%);
grade 3 (hospital admission) 12 (1.4%, 0.8% to 2.4%); and grade 4
(death) 0. Grade of adverse event was associated with an unfavourable
attitude to repeat biopsy (Kendall’s τ-b ordinal by ordinal 0.29, P<0.001).
Conclusion This study with a high response rate of 89% at 35 days in
men undergoing biopsy in the context of a randomised controlled trial
has shown that although prostate biopsy is well tolerated by most men,
it is associated with significant symptoms in a minority and affects
attitudes to repeat biopsy and primary care resource use. These findings
will inform men who seek PSA testing for detection of prostate cancer
and assist their physicians during counselling about the potential risks
and effect of biopsy. Variability in the adverse event profile between
centres suggests that patients’ outcomes could be improved and
healthcare use reduced with more effective administration of local
anaesthetic and antibiotics.
Trial registration Current Controlled Trials ISRCTN20141297.
Introduction
Prostate cancer is a major health problem worldwide; 899 000
new cases were diagnosed in 2008 (13.6% of total incident
cancers), and an estimated 258 000 deaths (6.1% of cancer
deaths) from the disease occurred.1 Recent evidence from large
European randomised studies of screening suggests a reduction
in disease specific mortality ranging between 20% and 44%,2 3
but at the cost of over-detection and potential overtreatment,4
which precludes the introduction of screening as public health
policy. While the debate continues, men who seek early
detection of prostate cancer by testing for prostate specific
antigen (PSA) need accurate information on the consequences
of the diagnostic process as well as the therapeutic dilemma. In
men who have PSA testing, prostate biopsy is needed for a
histological diagnosis of prostate cancer. Whereas considerable
attention has been paid to PSA testing, relatively little is known
about the effect of prostate biopsy in this group of otherwise
healthy men. One of the criteria for suitability of a test for
screening is that it is acceptable to the population being
screened. In the context of prostate cancer, this criterion is often
applied only to PSA testing but is also relevant in the context
of subsequent prostate biopsy to provide the definitive diagnosis.
Laboratories carrying out PSA testing for the National Health
Service are subject to quality assurance under the United
Kingdom National External Quality Assurance Service.
Comparatively, transrectal ultrasound guided prostate biopsy
(TRUS-Bx), the most commonly used technique for prostate
biopsy in these asymptomatic men, has received little attention
and is not subject to any similar external quality assurance.
TRUS-Bx was introduced more than two decades ago, initially
without any form of analgesia, for the detection of prostate
cancer.5 The procedure has evolved, primarily to improve the
rate of cancer detection by increasing the number of biopsy
cores taken.6 To reduce morbidity and improve tolerability of
increasing the number of cores, the use of prophylactic
antibiotics and analgesia in the form of intrarectal lidocaine gel
or periprostatic infiltration of local anaesthetic have become
commonplace, with considerable variability in practice and
outcomes.7 8 9 TRUS-Bx can be associated with appreciable
morbidity, including sepsis, pain, bleeding, and even death on
rare occasions. The true effect of biopsy is difficult to ascertain
from the literature—the reported morbidity is highly variable,
and although post-biopsy adverse events are often referred to
as “major” or “minor,” the basis of this classification is arbitrary
and inconsistent. The incidence of major complications in the
Rotterdam cohort of the European Randomized study of
Screening for Prostate Cancer (ERSPC) was 12% (7.5% pain,
4% fever, 0.5% hospital admission for sepsis, 0.4% admission
for acute urinary retention),10 in contrast with a reported
incidence of “major” complications of 0.1% in an Austrian
screened population (n=1051).11 A systematic review of
TRUS-Bx observed that only 41 of 87 studies made anymention
of adverse events, and where mention wasmade no standardised
approach to reporting was used.12 Furthermore, the acceptability
of re-biopsy is uncertain: in the era preceding widespread use
of local anaesthetic, a British study reported that 19% of men
refused re-biopsy without general anaesthesia,13 and the Finnish
study of screening for prostate cancer observed that 18% of
screened men would not accept a repeat biopsy.14 In contrast,
Djavan et al reported that of 820 Austrian men previously
biopsied, all re-attended for re-biopsy as an outpatient when
invited.11 The factors influencing this attitude towards repeat
biopsy remain uncertain, but it is important as around two thirds
of men initially have a negative biopsy and may need another.15
Thewide variability in adverse events and acceptability probably
reflects a combination of expertise, patients’ expectations, and
inconsistent reporting. Little evidence based information about
the experience of TRUS-Bx is available to share with men
having the procedure. Additionally, no systematic investigation
of the acceptability of TRUS-Bx and association between
adverse events after TRUS-Bx and attitude to re-biopsy in a
PSA-tested population has been done. The aims of this study
were to measure the effect of adverse events after a first prostate
biopsy in asymptomatic men having PSA testing; to assess early
attitudes to repeat biopsy; to estimate the effect of adverse events
from TRUS-Bx on healthcare resource use; and to develop a
simple classification system for consistent reporting of adverse
events after prostate biopsy.
Methods
Design and sample size
A prospective cohort study (ProBE—Prostate Biopsy Effects)
was embedded in the ongoing Prostate Testing for Cancer and
Treatment (ProtecT) study, which is a large multicentre
randomised controlled trial started some years previously to
evaluate the effectiveness, cost effectiveness, and acceptability
of treatments for men with localised prostate cancer.15 16General
medical practices in and around nine cities throughout the United
Kingdom recruited men to the ProtecT study. Lead partners of
the practices received letters of invitation for their practice to
participate in the study, detailing the rationale for a randomised
controlled trial of treatment in clinically localised prostate cancer
detected by PSA. Participating practices in turn sent letters
inviting men aged 50-69 years registered at the practice to attend
for PSA counselling. Nurse led clinics were held in a primary
care setting, where participants with an estimated life expectancy
of a minimum of 10 years and without important
cardiorespiratory comorbidity were given detailed information
about the implications of PSA testing, the uncertainties about
treatments, and the need for a treatment trial; consent was sought
thereafter for PSA testing. Biopsy was offered to all men with
a PSA concentration of 3.0 ng/mL or above. The sample size
calculation suggested that 880 participants would provide a
precise estimate of an expected hospital admission rate of 1%,10
with a 95% confidence interval of 0.4 to 2%. The target was to
enrol 1200 men, allowing a priori for a 25% dropout rate.
Population and exposure
In February 2006, the ProBE study started recruitment in eight
of the nine ProtecT centres. Men presenting with a PSA
concentration of 3.0-19.9 ng/mL, with no previous experience
of TRUS-Bx, were invited to participate in ProBE in addition
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to their involvement in the ProtecT study. As many practices
were part way through recruitment to ProtecT when ProBE
started and stopped recruitment, not all practices nor all men at
any given practice were offered the study.
The intention was for the ProBE study to recruit consecutive
men attending for a prostate biopsy in ProtecT from February
2006 until the sample size of 1200 was reached (see above).
Resource limitation at the height of recruitment to ProtecTmeant
that some biopsy sessions were not covered by research staff,
so not all men attending biopsy sessions were offered
participation in ProBE.
All men invited to join the ProBE study were given patients’
information sheets on ProBE as well as ProtecT, in addition to
local instructions related to the biopsy procedure. Baseline data
including weight, height, drug history, comorbidity, Hospital
Anxiety and Depression Scale (HADS) score, and urinary,
bowel, and sexual symptoms were assessed by using the
validated International Continence Society—male, International
Consultation on IncontinenceModular Questionnaire—urinary
incontinence, and University of California, Los Angeles Prostate
Cancer Index questionnaires.17 18 19 Outpatient TRUS-Bx was
carried out in the left lateral decubitus position under antibiotic
cover by using a 10 core lateral biopsy template.20 21 In a
pre-study questionnaire, seven of the eight centres reported
using periprostatic infiltration of local anaesthetic (1% or 2%
lidocaine) routinely before biopsy. All men received antibiotic
prophylaxis according to contemporary practice; inter-centre
variability existed, but each centre used a consistent schedule
throughout the study period. A midstream specimen of urine
was sent for culture immediately before antibiotic
administration. Coumarin anticoagulant and clopidogrel
treatment were discontinued up to 10 days before biopsy and
advice sought as to appropriate substitutes if indicated. Aspirin
was continued at the discretion of the physician doing the
biopsy. Men were kept under observation after the biopsy until
they voided. Urine was assessed for haematuria according to a
four point colorimetric scale. Each centre provided its own
post-biopsy written instructions and contact details.
Outcome measures
Symptoms
Men self reported pain and discomfort (referred to as pain
hereafter) immediately after and seven days after TRUS-Bx on
a four point Likert-type scale as none, mild, moderate, or severe.
Specific related complications such as fever, flu-like shivers,
pain, haematuria, haematochezia, and haemoejaculate were self
reported at seven and 35 days after TRUS-Bx as absent or
present following biopsy on a purpose designed questionnaire
(TRUS-BxQ; see appendix 1). This included the validated
International Continence Society—male, International
Consultation on IncontinenceModular Questionnaire—urinary
incontinence, and University of California, Los Angeles Prostate
Cancer Index questionnaires.17 18 19 For each reported symptom,
participants were asked to grade the degree of “problem”
associated with its presence as none, minor, moderate, or major.
We used this information to derive a binary outcome for each
symptom, as present with moderate/severe problem versus not
present/minor problem. During the pilot phase (February 2006
to April 2006), an expert committee (appendix 2) reviewed the
initial data from the TRUS-BxQ to optimise face validity and
content validity.
Attitude to re-biopsy
To assess attitudes to possible further biopsies immediately after
the biopsy and seven days later, men were asked to record on
a four point Likert-type scale (no problem, minor, moderate,
major problem) “howmuch of a problemwould you find having
another biopsy in the future?” Analyses explored the relations
between men’s reports of pain and symptoms and their attitude
to re-biopsy.
Healthcare resource use
Men reported any contact with healthcare services in the
TRUS-BxQ at seven and 35 days after biopsy. A non-clinical
research assistant did semi-structured telephone interviews with
men between seven and 10 days after biopsy.When self reported
data were unclear or missing, we searched medical records
(written and electronic) for any episode of contact with any
provider in primary or secondary care occurring within 35 days
of the date of biopsy. We used data from the participants’
interviews, TRUS-BxQ, and the review of hospital records to
ascertain the reason for any hospital admission. When contact
with primary care was detected or reported, we made an
assessment of its relevance to the biopsy procedure, on the basis
of a free text description provided by participants in the self
completed TRUS-BxQ and review of the clinical records where
necessary.
Adverse event classification
Wegrouped adverse events of fever, flu-like shivers, haematuria,
haematochezia, and haemoejaculate together as “infective,”
“haemorrhagic,” and combined “infective/haemorrhagic”
symptoms.We classified adverse events in a manner consistent
with the National Cancer Institute’s common toxicity criteria
version 3.0 as grade 0 = no adverse event reported and no biopsy
related healthcare contact, grade 1 = symptoms reported but
causing no/minor problem and no biopsy related healthcare
contact, grade 2 = symptom reported causing major/moderate
problem or biopsy related healthcare contact without hospital
admission, grade 3 = hospital admission within 35 days of
biopsy, and grade 4 = death within 35 days of biopsy.22 This
analysis included onlymenwith a complete dataset of symptoms
at both assessments.
Data analysis
We used SPSS statistical software version 18.0 to do data
analyses using the available data; we did not impute anymissing
data. We present the proportion of men who experienced each
outcome, with 95% confidence intervals calculated by using
Wilson’s method (CIA software, version 2.2.0, www.som.
southampton.ac.uk/cia). We estimated associations between
risk factors and binary outcome measures (for example,
moderate/major problem with re-biopsy, healthcare contact,
hospital admission) as odds ratios by using logistic regression
with adjustment for age and centre. For clarity, where the
symptom scale is reduced to a binary distinction, this
distinguishes men reporting a moderate/major problem from
those reporting a mild/no problem. We used the logistic
regression models as the basis of likelihood ratio tests to
calculate P values. We adjusted for age and recruitment centre
by adding dummy variables to the regression models—three
dummy variables distinguishing four age groups (50-54, 55-59,
60-64, and 65-69 years) and seven dummy variables
distinguishing eight study centres.
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Results
In the ProtecT study overall, of the 227 000 men aged 5069
years who were identified at 352 practices and invited to nurse
led clinics in the community for counselling about PSA testing,
111 148 attended. Of the 10 297 men offered TRUS-Bx within
ProtecT, 1753 attended for biopsy between February 2006 and
May 2008 and were eligible to enter the ProBE study; 1147
(65%) consented to participation. Table 1⇓ summarises baseline
data.
Of the 1147menwho had TRUS-Bxwithin ProBE, TRUS-BxQ
data were available for 1144 (99.7%) at baseline, 1090 (95.0%)
at seven days, and 1018 (88.8%) at 35 days post-biopsy.
Telephone follow-up, primary care, and hospital record data
were available for all 1147 participants. We found no difference
between the men recruited in the eight centres with regard to
age (P=0.086), PSA concentration (P=0.51), body mass index
(P=0.54), or HADS anxiety (P= 0.83) or depression scores
(P=0.2). A difference in mean prostate volume existed
(P<0.001).
Symptoms, degree of associated problem,
and duration
Immediately after biopsy, 37/1134 (3.3%, 95% confidence
interval 2.4% to 4.5%) men reported light-headedness and three
(0.3%, 0.1% to 0.8%) experienced a short period of syncope.
All men voided after the procedure. Moderate or severe
haematuria was present in 78/1055 (7.4%, 6.0% to 9.1%)
post-biopsy urine samples and was associated with large blood
clots in 27 (2.6%, 1.8% to 3.8%). Three additional men passed
clots without moderate or severe haematuria.
Table 2⇓ shows the number of men who reported pain, fever,
flu-like shivers, haematuria, haematochezia, and haemoejaculate
within seven and 35 days of biopsy and the proportion who
reported a moderate/major problem associated with each
symptom. Approximately one third of men (n=340/1147)
reported no sexual activity within 35 days after biopsy, and the
prevalence of haemoejaculate is therefore limited to those who
were sexually active during the study period. Although the
prevalence of each symptom and combination of symptoms was
relatively high, most men reported the presence of a symptom
as being no problem or a minor problem (table 2⇓ and box).
Attitude to repeat biopsy
Immediately after the procedure, 124/1142 (10.9%, 9.2% to
12.8%)men reported that having a repeat biopsywould represent
amoderate/major problem. This rose to 213/1085 (19.6%, 17.4%
to 22.1%) when the question was repeated seven days later
(P=0.001, McNemar’s test for a null hypothesis of no difference
in the proportion finding re-biopsy a moderate/major problem).
The proportion of men considering repeat biopsy to be a
moderate/major problem differed by centre at both time points
(P<0.001) (table 3⇓). These differences persisted following the
exclusion of centre 3 (P=0.004), where local anaesthetic was
not administered routinely.
A strong association existed between an unfavourable attitude
to repeat biopsy at seven days and pain reported at both time
points (immediately post-biopsy: odds ratio 12.1, P<0.001; at
seven days: odds ratio 8.2, P<0.001) as well as symptoms within
seven days related to infection (odds ratio 7.89, P<0.001) and
bleeding (4.24, P<0.001) (table 4⇓).
Healthcare contact
No deaths occurred in this cohort within 35 days of biopsy (95%
confidence interval 0 to 0.4%). In that period, 15/1147 (1.3%,
0.8% to 2.1%) men needed hospital admission for sepsis (n=7),
urinary retention (n=3), haematuria (n=2), rectal bleeding (n=1),
or other diagnoses (n=2). All admissions due to sepsis occurred
within three days of biopsy, whereas one man with retention
was admitted three weeks after biopsy. A further 119 (10.4%,
8.7% to 12.3%)men initiated a biopsy related consultation with
their general practitioner (n=92), urology department nurse (14),
or other source of medical advice (13) such as NHS Direct. The
predominant reasons for seeking healthcare advice in primary
care were infective symptoms (n=38), urinary symptoms
including haematuria (34), haemoejaculate (14), possibility of
antibiotic related adverse events such as diarrhoea or a skin rash
(14), and discomfort/bleeding on defecation (10). We found no
evidence that such contacts varied across centres (P=0.73).
Table 4⇓ lists selected variables examined for associations with
healthcare contact within 35 days. Biopsy related healthcare
contact within 35 days was more likely in men with a previous
history of urinary tract infection (P=0.036) compared with
others, and in men who reported moderate/severe pain
immediately after the procedure (P=0.017). Cross sectional
analysis showed a strong association between healthcare contact
and symptoms of infection, bleeding, or both at seven days
(P<0.001).
Owing to the low number of events, we could investigate only
crude associations with hospital admissions.We found evidence
of a higher risk of hospital admission in men treated with
non-steroidal agents (3/58 (5%) v 11/1035 (1.1%), P=0.037)
and those reporting a moderate/severe problem with symptoms
of infection (7/47 (15%) v 7/1036 (0.7%), P<0.001) or bleeding
(6/179 (3%) v 9/843 (1.1%), P=0.039) at 7 days. None of the
men with a history of prostatitis (n=18) or warfarin treatment
(n=14) or who had an infected midstream urine sample before
biopsy (n=18) were admitted to hospital within 35 days of the
procedure.
Adverse event classification
Complete data on the five index symptoms at seven and 35 days
were available for 851/1147 (74.2%)men.We classified adverse
events as grade 0 (no symptoms/contact) in 18 (2.1%, 1.3% to
3.3%), grade 1 (minor) in 550 (64.6%, 61.4% to 67.8%), grade
2 (moderate/major) in 271 (31.8%, 28.8% to 35.1%), and grade
3 (inpatient/hospital admission) in 12 (1.4%, 0.8% to 2.4%); no
participants had a grade 4 event (death). We found strong
evidence of an association between the grade of adverse event
at 35 days and an unfavourable attitude to repeat biopsy at seven
days (Kendall’s τ-b ordinal by ordinal 0.29, P<0.001).
Exploratory analyses
Prostate volume, age, and attitude to repeat
biopsy
We found weak evidence that older men were more likely to
report a favourable attitude to repeat biopsy than were younger
participants (odds ratio per 5 year increase in age between 50
and 69 years: 0.86, 0.75 to 1.00, P=0.056) (table 44). Men who
considered repeat biopsy to be a moderate/major problem were
more likely to have a smaller prostate volume (P=0.027) (table
4⇓).
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Box 1. Summary of adverse effects reported during 35 day follow-up period
Using a structured questionnaire, we asked more than 1000 men to record what their experience of a prostate biopsy had been both
immediately and up to 35 days after biopsy. This box summarises their responses.
Immediate effects
• 85% of men described no pain or mild pain associated with the biopsy procedure itself
• 3% of men felt “lightheaded” or dizzy after the biopsy
• 7% passed blood in their urine immediately after biopsy
• 3% passed “clots”’ in their urine immediately after biopsy
Delayed effects (in 35 days after biopsy)
• 44% of men had pain; 7% found this a moderate or serious problem
• 20% had a fever; 5% found this a moderate or serious problem
• 66% had blood in the urine; 6% found this a moderate or serious problem
• 37% had blood in the motions; 2% found this a moderate or serious problem
• 90% had blood in the semen; 25% found this a moderate or serious problem
Prolonged symptoms (two weeks or more after biopsy)
• 15% of men had some pain
• 3% had a fever
• 20% had blood in their urine
• 5% had blood in their motions
• 60% had blood in their semen
Prostate cancer diagnosis and healthcare contact
Prostate cancer was diagnosed on biopsy in 406/1147 (35.4%,
32.6% to 38.2%)men.We found a difference in cancer detection
rates ranging between 23% (14% to 36%) and 53% (40% to
65%) across the eight centres (P=0.008). We found no
convincing evidence that men subsequently diagnosed as having
cancer were more likely to come into contact with healthcare
services for a biopsy related adverse event within 35 days of
the procedure compared with men in whom cancer was not
diagnosed (48/406 (11.8%) v 87/741 (11.6%); odds ratio 1.03,
0.70 to 1.50, P=0.89, adjusted for age and study centre). The
risk of hospital admission was 1.7% in men subsequently
diagnosed as having cancer and 1.1% in those without cancer
(P=0.84).
Discussion
This multicentre prospective study with a high response rate of
89% at 35 days provides generalisable quantitative data about
the events occurring in the 35 days after a first prostate biopsy.
The findings are based on patient reported outcomes and
verifiable criteria, including healthcare resource use. Whereas
prostate biopsy was reasonably well tolerated in most men, a
few men rated post-biopsy pain and infective/haemorrhagic
symptoms as a major/moderate problem—7.3% for pain, 5.5%
for fever, 6.2% for haematuria, 2.5% for haematochezia, and
26.6% for haemoejaculate. Immediately after biopsy, 10.9%
reported that they would consider further biopsy a major or
moderate problem; seven days after biopsy, this proportion had
increased to 19.6%. A negative attitude to repeat biopsy was
associated with unfavourable experience after the first biopsy,
particularly pain at biopsy; differences were evident between
centres carrying out the biopsies. Consultation with a healthcare
professional (usually their general practitioner) was reported
by 10.4%, most commonly for infective symptoms.
Transrectal ultrasound guided biopsy of the prostate is an
ambulatory procedure commonly carried out in consulting rooms
and outpatient and radiology departments in small and large
hospitals. Although accurate figures for the number of
procedures carried out in the UK each year are difficult to elicit,
approximately 37 000 new cases of prostate cancer are diagnosed
annually (http://info.cancerresearchuk.org/cancerstats/types/
prostate), with a cancer detection rate at biopsy of around 35%.17
Assuming that around 100 000 procedures are carried out every
year in the UK alone would thus be reasonable.
The results of this study are particularly relevant to screening
for prostate cancer rather than the performance of prostate biopsy
for confirmation of a diagnosis in clinically evident disease.
The cohort is drawn from asymptomatic men, invited for PSA
testing in the context of a large randomised controlled trial
(ProtecT), with a first biopsy at a PSA concentration of 3.0-19.9
ng/mL, a range commonly held to be appropriate for detection
of localised prostate cancer suitable for treatment with curative
intent. None of the men had repeat biopsy during the timeframe
specified. Particular emphasis was placed on the perception of
the man having the biopsy, as well as the identification of
adverse events. This emphasis allowed the study to measure
how a man perceives the degree of “problem” associated with
individual symptoms resulting from a first prostate biopsy. Cross
referencing these perceptions with healthcare resource use
provided useful triangulation. Maintaining a high response rate
of 95% at seven days and 89% at 35 days is a particular strength
of the study.
A significant number of men experienced difficulties during or
after the biopsy, primarily associated with pain, sepsis, or
bleeding. Very fewmen experienced no symptoms at all (2.1%,
grade 0) in the five weeks after biopsy. Of those who did
experience one or more symptoms, most considered them to be
of little consequence (64.6%, grade 1). The remaining third
experienced adverse events that they considered to be amoderate
or severe problem. Of interest, the presence of blood in a man’s
ejaculate (haemoejaculate) after biopsy is seldom reported in
the literature and is often labelled as a “minor” adverse event.
In this study, haemoejaculate was perceived as a moderate to
severe problem for around one quarter of sexually active men
(table 2⇓). Further investigation of the problems generated by
this symptom is warranted, and information about its duration
and persistence should be given to all men having biopsies.
During initial counselling before PSA testing, men are informed
of the possible requirement for repeat biopsies beyond the first
procedure, in the event of equivocal results or a benign biopsy
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with persistent risk factors such as a persistently raised serum
PSA concentration. A recent study from the United States
reported that 38% of men having a first biopsy will have a repeat
procedure within five years of the initial biopsy; the proportion
reaches 44% in men under the age of 70 years.23 Several studies
have shown that repeat biopsy leads to a detection rate for
prostate cancer of 19-59%,24 25 26 so understanding how a first
biopsy affects a man’s attitude to additional procedures if needed
is essential. In this study, 11% and 20% of men reported an
unfavourable attitude to repeat biopsy immediately after biopsy
and seven days later; pain experienced at biopsy and infective
symptoms in the week after biopsy were strongly associated
with this response. Systematic TRUS-Bxwas introduced initially
without local anaesthetic, although this has been adopted in
clinical practice more recently.5 8 9 27 Meta-analyses have
described a significant reduction in pain scores with periprostatic
nerve blocks28 29; doubt remains, however, as to whether the
reduction in pain scores translates to clinically meaningful
changes, particularly as infiltration of local anaesthetic itself
has been shown to be associated with pain.30 The association
between levels of pain experienced and attitude to having repeat
biopsy described in this study is an important observation that
supports the mandatory use of periprostatic nerve blockade with
local anaesthetic. Even among centres where local anaesthetic
was routinely administered, inter-centre variability in its effect
existed. This suggests that the technique of administration may
need to be standardised to ensure effectiveness of local
anaesthesia.
As well as resulting in a negative attitude to re-biopsy, infective
complications were the most common reason for seeking
medical advice or primary care intervention (10.4%). Most
symptoms were evident within seven days of biopsy, with a
small proportion of men continuing to report symptoms for up
to five weeks after biopsy (box). This information is particularly
valuable for general practitioners when counselling patients
before PSA testing. The American Urological Association’s
best practice policy statement recommends administration of a
fluoroquinolone as uniform antimicrobial prophylaxis in all
men having TRUS-Bx.31 Current practice, however, has been
influenced predominantly by randomised controlled trials
indicating the efficacy of a single dose of ciprofloxacin in
reducing the incidence of infective complications after
TRUS-Bx32 33; subsequent studies have suggested that prolonging
treatment to three days results in superior clinical effectiveness.34
A recent report has identified an increasing rate of sepsis related
admission to hospital after prostate biopsy in the decade between
1996 (0.6%) and 2005 (3.6%).35 This may be related to a general
reduction in peri-biopsy antibiotic use,36 but the development
of quinolone resistance may also be implicated.37 38 39 40 Against
this backdrop, antibiotic prophylaxis for TRUS-Bx is universally
used, but without consensus on best practice.41 We have shown
some evidence of differences in infective complications between
centres, but our study was not specifically designed to evaluate
the effectiveness of antibiotic prophylaxis; this warrants further
prospective investigation.
The classification of adverse events described in this study is
similar to that described after systemic chemotherapy. It is based
on a combination of reported events and their effect from a
patient’s perspective. Its wider use needs further validation and
is likely to show the need to standardise and refine the technique
of prostate biopsy to minimise its adverse events. No fatal events
occurred in our cohort. This is not surprising, as our participants
were relatively healthy with an upper age limit of 69 years and
no symptoms. Mortality after prostate biopsy has been reported
as ranging between 0.09% and 1.3% at 120 days,35 42 and it is
associated with older, less healthy men.
In contrast with a large retrospective Canadian study referred
to earlier,35 we found no difference in our prospective study in
hospital admission rate (grade 3 adverse event) between
participants with cancer and those without (1.7% v 1.1%). The
findings of the Canadian studymay result from the investigation
of a population at different risk or, as acknowledged by the
authors, from inaccuracy in coding associated with its
retrospective nature.
Limitations of study
The ProBE study cohort included asymptomatic men aged
between 50 and 69 years presenting for a first prostate biopsy
after a PSA test, received through the ProtecT study during the
period February 2006 to May 2008. The ProBE study was
carried out over this limited period, sampling approximately
11% of the ProtecT participants. The cohort did not include
men seen in routine UK clinical practice with urinary symptoms
or clinically suspected prostate cancer. Of the men eligible for
inclusion, 65% were recruited and thus are likely to be
representative of the men who attended for PSA testing within
the ProtecT study. Embedding the ProBE study in the ProtecT
trial was beneficial, providing a standardised biopsy template
and recruitment from a wide range of practices across the UK
and improving compliance with follow-up. However,
participants had responded to a single written invitation to attend
for PSA testing sent out via general practices, so non-responders
may not be represented in this study. The observations are likely
to remain valid in the context of men seeking PSA testing for
detection of prostate cancer.
In the absence of nationally agreed, evidence based patient
information leaflets, each centre delivered its own information
about the biopsy process, which may have influenced men’s
views. Recall bias may also have occurred for recording the
duration of symptoms, as men were asked to summarise their
experience over the previous four weeks in the 35 day
questionnaire. For the main analyses, we required data with
evaluable responses from both the seven day and 35 day
questionnaire assessments. This reduced the numbers and may
have led to some degree of underestimation of the prevalence
of adverse events. Although relevant to the overall outcome,
some of the reported symptoms (such as fever/shivers) may not
have been related to the biopsy itself andmay have inadvertently
influenced a negative attitude to repeat biopsy.
Additional items
Administration of local anaesthesia is important in determining
pain experienced, but other factors, such as environment,
training, education, and nursing care, will clearly affect anxiety
and pain. We have explored some of these factors in a linked
qualitative study (data not included). Similarly, although we
have sought men’s initial and early views on the acceptability
of repeat biopsy, attitudes may change with time; we shall
therefore follow up this cohort carefully to analyse the re-biopsy
rate and assess patients’ subsequent views.
While healthcare providers await further evidence to decide
whether screening for prostate cancer should become public
health policy, primary care physicians need to be well informed
of the risks and adverse events related to TRUS-Bx as well as
PSA before testing. The findings of this study contribute further
generalisable quantitative data about the potential harms
associated with making a diagnosis of prostate cancer in
asymptomatic men.
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Generalisability
The ProBE study investigated a large cohort of men aged
between 50 and 69 years who had TRUS-Bx for the first time
as a result of a PSA concentration between 3.0 and 20 ng/mL.
The cohort comprised 65% of eligible men biopsied within a
trial population. The results are likely to be generalisable to all
asymptomatic men in this age group who seek diagnosis of
prostate cancer through PSA testing and in the context of
screening. They may, however, not be applicable to younger or
older men, those with clinical evidence of prostate cancer, or
men who have previously had prostate biopsy.
Conclusions
After prostate biopsy, one third of men having first time
TRUS-Bx for a high PSA reported moderate to severe biopsy
related symptoms. Immediately after TRUS-Bx, one in 10 men
had an unfavourable attitude to repeat biopsy, rising to one in
five later. This was associated with adverse events in the seven
days after biopsy and seemed to affect younger men more; as
these men are most likely to benefit from early diagnosis of
prostate cancer as well as require re-biopsy, this requires further
investigation. Within 35 days of biopsy, 1.3% of men required
admission to hospital and a further 119 (10.4%) men initiated
a biopsy related consultation with their general practitioner
(n=92), urology department nurse (n=14), or other source of
medical advice (n=13) such as NHS Direct, most commonly
for infective symptoms. The adverse event classification scheme
described may help to show variation in rates of adverse events
across centres that arise from differences in information and
biopsy technique. Training, protocols, and consistent reporting
methods should be considered to achieve excellence in practice.
Information for patients about biopsy should be standardised
and include the findings of this study, so that men and physicians
are fully informed about the risks and benefits of the diagnostic
process before they embark on prostate cancer detection.
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who were sexually active had haemoejaculate; all symptoms were less prevalent at 35 days
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with one in four describing this as a moderate/major problem
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Tables
Table 1| Summary statistics for baseline measures overall and at each centre
P value for
between
Centre number
Total
cohortCharacteristics 87654321
centre
differences
61561021151491762062821147No of biopsies
0.09*62.9 (5.1)62.2 (5.7)62.5 (5.1)61.9 (4.9)61.8 (5.1)61.2 (5.4)62.8 (4.6)62.0 (5.0)62.1 (5.1)
Mean (SD) age
(years)
0.69†
4.1 (3.4 to
5.3)
4.8 (3.6 to
6.9)
4.3 (3.5 to
5.6)
4.1 (3.5 to
5.8)
4.2 (3.5 to
5.8)
4.2 (3.4 to
5.4)
4.3 (3.5 to
6.1)
4.3 (3.5 to
5.8)
4.2 (3.5 to
5.8)
Median (interquartile
range) PSA (ng/mL)
0.54*27.5 (3.2)28.1 (4.4)27.7 (3.7)27.8 (3.8)27.1 (3.6)27.9 (3.4)27.1 (3.3)27.3 (3.8)27.4 (3.6)
Mean (SD) bodymass
index (kg/m2)
0.83*4.9 (3.5)4.5 (2.9)4.9 (3.2)4.6 (2.7)4.8 (3.6)5.2 (3.3)5.0 (3.4)4.8 (3.2)4.9 (3.3)
Mean (SD) HADS
(anxiety)
0.2*3.3 (2.9)2.4 (2.2)3.1 (2.4)2.7 (2.5)3.0 (2.8)3.4 (2.8)3.3 (2.7)3.2 (2.5)3.1 (2.7)
Mean (SD) HADS
(depression)
<0.001†46 (36 to 55)42 (35 to 57)31 (24 to 41)32 (27 to 39)44 (32 to 65)31 (24 to 43)47 (34 to 66)38 (30 to 53)38 (28 to 52)
Median (interquartile
range) prostate
volume (mL)
HADS=Hospital Anxiety and Depression Scale; PSA=prostate specific antigen.
*From ordinary least squares regression.
†From non-parametric comparison of medians.
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Table 2| Specific symptoms—prevalence and association with moderate or severe problem within 7 days and within 35 days
Moderate/serious problem (MS)*Symptom present
Symptom reported % (95% CI)MS/respondents% (95% CI)Reporting/respondents
Within 7 days
5.7 (4.4 to 7.3)62/108539.0 (36.2 to 42.4)425/1089Pain
4.0 (3.0 to 5.4)44/108811.7 (10.0 to 13.8)128/1090Fever
3.2 (2.3 to 4.5)35/108612.4 (10.6 to 14.5)135/1089Shivers
4.8 (3.6 to 6.3)52/107463.9 (61.0 to 66.7)693/1085Haematuria
1.7 (1.0 to 2.7)18/106132.9 (30.0 to 35.8)354/1076Haematochezia
20.0 (17.2 to 23.1)148/74086.3 (83.7 to 88.6)645/747Haemoejaculate†
22.4 (19.5 to 25.6)160/71494.0 (92.1 to 95.5)691/735Any infective/haemorrhagic
symptom‡
19.3 (17.0 to 21.9)196/101389.4 (87.4 to 91.1)936/1047Any infective/haemorrhagic
symptom§
Within 35 days¶
7.3 (5.7 to 9.1)71/97743.6 (40.5 to 46.7)429/984Pain
5.5 (4.2 to 7.1)54/98117.5 (15.2 to 20.0)172/985Fever
5.0 (3.7 to 6.6)49/97918.8 (16.5 to 21.3)185/985Shivers
6.2 (4.7 to 7.9)59/95865.8 (62.7 to 68.7)642/976Haematuria
2.5 (1.6 to 3.7)24/95136.8 (33.8 to 39.9)356/967Haematochezia
26.6 (23.3 to 30.2)172/64692.6 (90.4 to 94.4)605/653Haemoejaculate†
29.7 (26.2 to 33.4)181/61096.9 (95.2 to 98.0)622/642Any infective/haemorrhagic
symptom‡
27.1 (24.2 to 30.1)240/88794.0 (92.3 to 95.4)881/937Any infective/haemorrhagic
symptom§
*Presence of symptom causing moderate or severe problem.
†Excludes 339 men reporting no sexual activity at either 7 or 35 day assessment.
‡One or more of fever, shivers, haematuria, haematochezia, and haemoejaculate, excluding men reporting no sexual activity at either 7 or 35 day assessment.
§One or more of fever, shivers, haematuria, haematochezia, and haemoejaculate, including men reporting no sexual activity at either 7 or 35 day assessment.
¶Includes only men with evaluable data for both 7 day and 35 day assessments.
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Table 3| Pain and report of attitude to re-biopsy across eight study centres
7 day report: problem with re-biopsy
Immediate report
No of biopsiesCentre
Problem with re-biopsyPain
% (95% CI)MS/response*% (95% CI)MS/response*% (95% CI)MS/response*
11 (8 to 15)30/2708 (6 to 1223/2817 (5 to 11)21/2822821
20 (15 to 26)38/19211 (7 to 16)22/20618 (13 to 24)37/2052062
30 (23 to 37)50/16821 (16 to 28)37/17636 (30 to 44)63/1741763
15 (10 to 23)21/1366 (3 to 11)9/1476 (3 to 11)9/1471494
21 (15 to 30)23/1098 (4 to 14)9/11314 (9 to 22)16/1131155
18 (11 to 27)17/969 (5 to 16)9/10211 (6 to 18)11/1021026
35 (23 to 48)19/5514 (7 to 26)8/5614 (7 to 26)8/56567
25 (16 to 38)15/5911 (6 to 22)7/6111 (6 to 22)7/61618
19.6 (17.4 to 22.1)213/108510.9 (9.2 to 12.8)124/114215.1 (13.1 to 17.3)172/11401147Total
<0.001<0.001<0.001P value†
*Number of men reporting moderate or severe problem/number responding.
†Age adjusted test of null hypothesis (no between centre difference).
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Table 4| Associations between factors assessed at time of biopsy or at 7 day assessment (cross sectional analysis) and reportingmoderate
or major problem with re-biopsy 7 days after biopsy and contact with health services for biopsy related problem within 35 days of biopsy
Healthcare contactProblem with re-biopsySummary statistics in predictors for
overall cohortFactors P value*Odds ratio (95% CI)P value*Odds ratio (95% CI)
0.0171.81 (1.13 to 2.90)<0.0018.20 (5.54 to 12.13)172/1140 (15.1%)Pain of biopsy
<0.00116.78 (8.73 to 32.27)<0.0017.89 (4.16 to 14.94)47/1083 (4.3%)Infective symptoms at 7 days
<0.0012.89 (1.88 to 4.44)<0.0014.24 (2.92 to 6.15)179/1022 (17.5%)Haemorrhagic symptoms at 7 days
0.251.11 (0.93 to 1.34)0.0560.86 (0.75 to 1.00)Mean 62.1 (SD 5.1) years (n=1147)Age (odds ratio per 5 years)
0.0721.16 (0.99 to 1.37)0.0270.82 (0.69 to 0.99)Mean 43.5 (SD 22.8) mL (n=1062)Prostate volume (odds ratio per 20 mL)
0.0361.99 (1.08 to 3.65)0.910.96 (0.52 to 1.79)81/1097 (7.4%)History of urinary tract infection
0.0652.99 (1.02 to 8.76)0.551.41 (0.47 to 4.18)18/1094 (1.6%)History of prostatitis
0.0912.69 (0.93 to 7.80)0.841.15 (0.32 to 4.15)18/1078 (1.7%)Positive midstream urine at biopsy
0.0972.99 (0.91 to 9.85)0.300.38 (0.05 to 3.00)14/1091 (1.3%)Warfarin treatment
0.751.12 (0.56 to 2.22)0.891.04 (0.59 to 1.85)81/1055 (7.7%)Haematuria/clots in first voided urine
0.550.87 (0.54 to 1.39)0.480.87 (0.58 to 1.29)244/1096 (22.3%)Aspirin treatment
0.710.85 (0.35 to 2.04)0.290.68 (0.32 to 1.43)58/1093 (5.3%)NSAID treatment
Odds ratios and P values are adjusted for age and centre.
NSAID=non-steroidal anti-inflammatory drug.
*Calculated with likelihood ratio tests.
No commercial reuse: See rights and reprints http://www.bmj.com/permissions Subscribe: http://www.bmj.com/subscribe
BMJ 2012;344:d7894 doi: 10.1136/bmj.d7894 (Published 9 January 2012) Page 12 of 12
RESEARCH
